MabVax aims to price public sale of 6,629,834 common shares at $1.81

Bookrunner Laidlaw raises funds for general corporate purposes

By Devika Patel

Knoxville, Tenn., Aug. 14 – MabVax Therapeutics Holdings, Inc. will sell 6,629,834 common shares in its public offering with a 30-day greenshoe of 994,475 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The company has registered up to $13.8 million of stock for the deal, which was announced on June 8.

The shares will be sold at an expected price of $1.81 per share, which was the closing price of the stock on Aug. 12.

Laidlaw & Co. (UK) Ltd. is the bookrunning manager.

Proceeds will be used for working capital and general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.